Novartis chief gives up payout after storm of protest

Novartis chief gives up payout after storm of protest
Updated 20 February 2013
Follow

Novartis chief gives up payout after storm of protest

Novartis chief gives up payout after storm of protest

ZURICH: The outgoing head of Swiss pharmaceuticals giant Novartis, Daniel Vasella, has agreed to give up a massive payout, he said after a nationwide storm of protest.
“I have understood that many people in Switzerland find the amount of the compensation linked to the non-compete agreement unreasonably high, despite the fact I had announced my intention to make the net amount available for philanthropic activities,” Vasella said in a statement released by Novartis.
“That is why I have recommended to the board that I forgo all payments linked to the non-compete agreement,” he added.
Vasella, who has been at the helm since 1996, is due to step down as chairman of the Novartis board on Friday.
Under a recently-disclosed deal barring the 59-year-old from working for Novartis’ competitors, he was to receive an annual payout of 12 million Swiss francs (nine million euros, $ 13 million) over the next six years.
Provided he met all the conditions, that would have made him a total of 72 million Swiss francs.
The sum caused outrage among politicians across Switzerland’s spectrum, while the tabloid Blick summed it up as “insane,” and campaigners for shareholders’ rights filed a lawsuit.
The announcement of the amount came ahead of a March 3 referendum — the bedrock of Switzerland’s direct democracy — in which the country will decide whether to give company shareholders more power to rein in executive pay. Polls have shown that two-thirds of voters are likely to support the move.
Despite Vasella’s renouncing the pay-off, Novartis insisted that such deals where essential in the business world.

“Intended to protect the company, the non-compete required that Dr. Vasella refrain from making his knowledge and know-how available to competitors who may take advantage of his experience with the company,” it said.
“Dr. Vasella knows the company’s business intimately, having built the leading R&D organization and personally recruited most of the top executives,” it added.